{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.5","upperLimit":"49.5","value":"15.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"}],"units":"Participants"}],"description":"Will be computed with corresponding exact 95% confidence intervals based on the methodology of Clopper and Pearson. Will be obtained using the product-limit based Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive fludarabine phosphate IV over 30 minutes on days -6 to -2 and cyclophosphamide IV over 2 hours on days -6 and -5. Patients undergo TBI on days -1 and PBSCT on day 0.\n\nCyclophosphamide: Given IV\n\nFludarabine Phosphate: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPeripheral Blood Stem Cell Transplantation: Undergo PBSCT\n\nTotal-Body Irradiation: Undergo TBI","id":"OG000","title":"Treatment (Fludarabine, Cyclophosphamide, TBI, PBSCT)"}],"paramType":"MEDIAN","populationDescription":"All treated and eligible patients","reportingStatus":"POSTED","timeFrame":"up to 5 years and 8 months","title":"Progression Free Survival","type":"SECONDARY","unitOfMeasure":"months"}